These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31884676)

  • 21. Enhanced passive safety surveillance of three marketed influenza vaccines in the UK and the Republic of Ireland during the 2017/18 season.
    Gandhi-Banga S; Chabanon AL; Eymin C; Caroe T; Butler K; Moureau A
    Hum Vaccin Immunother; 2019; 15(9):2154-2158. PubMed ID: 30897026
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid assessment of enhanced safety surveillance for influenza vaccine.
    Alguacil-Ramos AM; Portero-Alonso A; Pastor-Villalba E; Muelas-Tirado J; Díez-Domingo J; Sanchis-Ferrer A; Lluch-Rodrigo JA
    Public Health; 2019 Mar; 168():137-141. PubMed ID: 30769245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapid safety assessment of a seasonal intradermal trivalent influenza vaccine.
    Demeulemeester M; Lavis N; Balthazar Y; Lechien P; Heijmans S
    Hum Vaccin Immunother; 2017 Apr; 13(4):889-894. PubMed ID: 27960593
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study.
    Treanor JT; Albano FR; Sawlwin DC; Graves Jones A; Airey J; Formica N; Matassa V; Leong J
    Vaccine; 2017 Apr; 35(15):1856-1864. PubMed ID: 28302411
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled study.
    Pepin S; Szymanski H; Rochín Kobashi IA; Villagomez Martinez S; González Zamora JF; Brzostek J; Huang LM; Chiu CH; Chen PY; Ahonen A; Forstén A; Seppä I; Quiroz RF; Korhonen T; Rivas E; Monfredo C; Hutagalung Y; Menezes J; Vesikari T
    Hum Vaccin Immunother; 2016 Dec; 12(12):3072-3078. PubMed ID: 27565435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults.
    Gorse GJ; Falsey AR; Ozol-Godfrey A; Landolfi V; Tsang PH
    Vaccine; 2015 Feb; 33(9):1151-9. PubMed ID: 25613721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative Postmarket Safety Profile of Adjuvanted and High-Dose Influenza Vaccines in Individuals 65 Years or Older.
    Pillsbury AJ; Fathima P; Quinn HE; Cashman P; Blyth CC; Leeb A; Macartney KK
    JAMA Netw Open; 2020 May; 3(5):e204079. PubMed ID: 32369177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Passive enhanced safety surveillance for Vaxigrip and Intanza 15 µg in the United Kingdom and Finland during the northern hemisphere influenza season 2015/16.
    Bricout H; Chabanon AL; Souverain A; Sadorge C; Vesikari T; Caroe TD
    Euro Surveill; 2017 May; 22(18):. PubMed ID: 28494843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults ≥50years of age: Results from a phase III, randomized, non-inferiority trial.
    Ofori-Anyinam O; Leroux-Roels G; Drame M; Aerssens A; Maes C; Amanullah A; Schuind A; Li P; Jain VK; Innis BL
    Vaccine; 2017 Nov; 35(46):6321-6328. PubMed ID: 28987445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and safety of a quadrivalent inactivated influenza virus vaccine compared with a comparator quadrivalent inactivated influenza vaccine in a pediatric population: A phase 3, randomized noninferiority study.
    Airey J; Albano FR; Sawlwin DC; Jones AG; Formica N; Matassa V; Leong J
    Vaccine; 2017 May; 35(20):2745-2752. PubMed ID: 28390934
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anamnestic Immune Response and Safety of an Inactivated Quadrivalent Influenza Vaccine in Primed Versus Vaccine-Naïve Children.
    Claeys C; Chandrasekaran V; García-Sicilia J; Prymula R; Díez-Domingo J; Brzostek J; Marès-Bermúdez J; Martinón-Torres F; Pollard AJ; Růžková R; Carmona Martinez A; Ulied A; Miranda Valdivieso M; Faust SN; Snape MD; Friel D; Ollinger T; Soni J; Schuind A; Li P; Innis BL; Jain VK
    Pediatr Infect Dis J; 2019 Feb; 38(2):203-210. PubMed ID: 30325891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Technical guidelines for seasonal influenza vaccination in China (2019-2020)].
    National Immunization Advisory Committee (NIAC) Technical Working Group (TWG), Influenza Vaccination TWG
    Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Jan; 54(1):21-36. PubMed ID: 31914565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunization of preterm infants with GSK's hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity.
    Omeñaca F; Vázquez L; Garcia-Corbeira P; Mesaros N; Hanssens L; Dolhain J; Gómez IP; Liese J; Knuf M
    Vaccine; 2018 Feb; 36(7):986-996. PubMed ID: 29336924
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Active surveillance of 2017 seasonal influenza vaccine safety: an observational cohort study of individuals aged 6 months and older in Australia.
    Pillsbury AJ; Glover C; Jacoby P; Quinn HE; Fathima P; Cashman P; Leeb A; Blyth CC; Gold MS; Snelling T; Macartney KK
    BMJ Open; 2018 Oct; 8(10):e023263. PubMed ID: 30341132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.
    Pépin S; Donazzolo Y; Jambrecina A; Salamand C; Saville M
    Vaccine; 2013 Nov; 31(47):5572-8. PubMed ID: 24016810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Technical guidelines for seasonal influenza vaccination in China, 2019-2020].
    National Immunization Advisory Committee (NIAC) Technical Working Group (TWG), Influenza Vaccination TWG
    Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Nov; 40(11):1333-1349. PubMed ID: 31838802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18-60 years of age in the Republic of Korea.
    Choi WS; Noh JY; Lee J; Choi JY; Lee JS; Kim MS; Kim HS; Bang J; Lavis N; Kim WJ
    Hum Vaccin Immunother; 2018 Mar; 14(3):587-592. PubMed ID: 28933625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine.
    Levin MJ; Buchwald UK; Gardner J; Martin J; Stek JE; Brown E; Popmihajlov Z
    Vaccine; 2018 Jan; 36(1):179-185. PubMed ID: 28830693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in children 6-59 months of age: A phase 3, randomized, noninferiority study.
    Statler VA; Albano FR; Airey J; Sawlwin DC; Graves Jones A; Matassa V; Heijnen E; Edelman J; Marshall GS
    Vaccine; 2019 Jan; 37(2):343-351. PubMed ID: 30057283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced passive safety surveillance of a trivalent and a quadrivalent influenza vaccine in Denmark and Finland during the 2018/2019 season.
    Serradell L; Wagué S; Moureau A; Nissilä M; Chabanon AL
    Hum Vaccin Immunother; 2021 Apr; 17(4):1205-1210. PubMed ID: 32966139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.